Prime Healthcare Services - ST Francis LLC
Prime Healthcare Services - ST Francis LLC was paid $27.65M by Medicaid between Aug 2020 and Dec 2024, across 263 billing codes. Its largest line is 0450, Emergency room services — 15% of everything it billed.
LYNWOOD, CA 90262
Next to other General Acute Care Hospital providers in California
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 38,320 | $1.05M | |
| 2021 | 189,358 | $7.25M | |
| 2022 | 248,638 | $8.23M | |
| 2023 | 281,512 | $6.20M | |
| 2024incomplete | 240,213 | $4.93M |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0450 | Emergency room services | 15% | 90,793 | 80,704 | $4.10M |
| 0121 | 12% | 571 | 543 | $3.19M | |
| 0214 | 7.6% | 437 | 418 | $2.11M | |
| Z7502 | 3.7% | 27,310 | 26,871 | $1.03M | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.4% | 5,313 | 5,162 | $932K |
| 0122 | 3.2% | 545 | 536 | $885K | |
| 70450 | Computed tomography, head or brain; without contrast material | 3.1% | 8,490 | 8,237 | $850K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 2.7% | 16,601 | 15,005 | $749K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.4% | 2,090 | 1,985 | $661K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.1% | 25,910 | 24,140 | $583K |
| 80053 | Comprehensive metabolic panel | 2.1% | 55,328 | 51,664 | $569K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.8% | 24,959 | 22,136 | $511K |
251 more codes
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.8% | 9,628 | $504K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.6% | 64,652 | $442K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 1.4% | 12,543 | $375K |
| 72125 | Computed tomography, cervical spine; without contrast material | 1.2% | 2,884 | $332K |
| 93976 | 1.1% | 1,804 | $301K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.0% | 14,495 | $287K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 8,797 | $269K |
| 99284 | Emergency room visit (serious) | <1% | 2,059 | $269K |
| 99199 | Unlisted special service, procedure or report | <1% | 7,729 | $262K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 5,805 | $261K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 3,601 | $250K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 4,527 | $236K |
| 0171 | Inj, epinephrine (belcher) | <1% | 555 | $223K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,372 | $221K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 6,089 | $218K |
| Z7610 | <1% | 18,114 | $213K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,400 | $201K |
| 0270 | <1% | 26,282 | $200K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 3,043 | $199K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 11,077 | $195K |
| 71045 | Radiologic examination, chest; single view | <1% | 15,346 | $190K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 4,102 | $178K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 1,569 | $166K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 5,359 | $161K |
| 84484 | <1% | 18,673 | $159K | |
| 0250 | <1% | 47,547 | $156K | |
| 0300 | <1% | 4,663 | $155K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 2,350 | $155K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,544 | $142K |
| 99283 | Emergency room visit (moderate) | <1% | 2,024 | $140K |
| Z9725 | <1% | 3,217 | $138K | |
| 76801 | <1% | 3,240 | $134K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 821 | $129K |
| 93971 | <1% | 1,286 | $127K | |
| 81025 | <1% | 22,258 | $124K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 21,521 | $121K |
| 0761 | <1% | 4,503 | $120K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,220 | $115K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 15,578 | $114K |
| 83690 | <1% | 17,364 | $103K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,175 | $97K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 15,120 | $95K |
| 83880 | <1% | 3,879 | $92K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,332 | $88K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 3,074 | $86K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,076 | $86K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 11,739 | $82K |
| 81001 | <1% | 28,536 | $80K | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 649 | $77K |
| 76830 | Ultrasound, transvaginal | <1% | 1,349 | $77K |
| 90715 | <1% | 2,063 | $67K | |
| 84702 | <1% | 6,501 | $67K | |
| 99152 | <1% | 1,413 | $59K | |
| 70486 | <1% | 542 | $58K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 6,934 | $54K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 1,426 | $53K |
| 76770 | <1% | 837 | $53K | |
| 87040 | <1% | 6,081 | $53K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,078 | $50K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,872 | $49K |
| 73030 | <1% | 2,319 | $48K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 622 | $47K |
| 73610 | <1% | 2,007 | $45K | |
| 73562 | <1% | 2,241 | $43K | |
| 93970 | <1% | 272 | $42K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 685 | $42K |
| 73130 | <1% | 1,869 | $41K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,516 | $40K |
| 73630 | <1% | 1,840 | $39K | |
| 0360 | <1% | 1,076 | $39K | |
| 83605 | <1% | 4,224 | $37K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 4,973 | $36K |
| 0510 | <1% | 1,057 | $34K | |
| 0301 | <1% | 2,795 | $30K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 956 | $30K |
| 59025 | Fetal non-stress test | <1% | 1,618 | $30K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,535 | $30K |
| 87420 | <1% | 5,422 | $30K | |
| 73564 | <1% | 1,106 | $29K | |
| 0272 | <1% | 9,789 | $28K | |
| 85730 | <1% | 5,781 | $28K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,341 | $26K |
| 72131 | <1% | 241 | $26K | |
| 73110 | <1% | 1,256 | $26K | |
| 73502 | <1% | 1,026 | $25K | |
| 87186 | <1% | 3,380 | $24K | |
| 0682 | <1% | 461 | $23K | |
| 0636 | <1% | 6,632 | $23K | |
| 81003 | <1% | 10,659 | $22K | |
| 77300 | <1% | 54 | $22K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,540 | $22K |
| 72100 | <1% | 793 | $21K | |
| 85610 | <1% | 6,308 | $20K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 825 | $20K |
| 73590 | <1% | 1,052 | $19K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 485 | $19K |
| J3490 | Unclassified drugs | <1% | 7,072 | $19K |
| 76818 | <1% | 1,188 | $19K | |
| 0001A | <1% | 491 | $19K | |
| 76870 | <1% | 426 | $18K | |
| 77336 | <1% | 325 | $18K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,382 | $18K |
| 86901 | <1% | 6,391 | $17K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 27 | $16K |
| 86900 | <1% | 6,366 | $15K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 26,927 | $15K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,736 | $15K |
| 85379 | <1% | 1,661 | $13K | |
| 86850 | <1% | 3,067 | $13K | |
| 0760 | <1% | 1,754 | $13K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 44 | $13K |
| 76775 | <1% | 344 | $12K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 185 | $12K |
| 73090 | <1% | 706 | $12K | |
| 0002A | <1% | 287 | $11K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,375 | $11K |
| 77290 | <1% | 60 | $11K | |
| 73080 | <1% | 449 | $10K | |
| 87088 | <1% | 1,825 | $10K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 8,272 | $10K |
| 0160 | <1% | 257 | $9K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 229 | $9K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,127 | $9K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,251 | $9K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,749 | $9K |
| 82962 | <1% | 3,647 | $9K | |
| 99221 | <1% | 284 | $8K | |
| 0710 | <1% | 936 | $8K | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 1,652 | $8K |
| 74018 | <1% | 541 | $8K | |
| 0762 | <1% | 105 | $7K | |
| 86141 | <1% | 828 | $7K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,092 | $7K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,307 | $7K |
| J2704 | Injection, propofol, 10 mg | <1% | 763 | $7K |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 44 | $7K |
| 83735 | <1% | 1,330 | $7K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,390 | $7K |
| 77417 | <1% | 220 | $6K | |
| 85027 | <1% | 1,119 | $6K | |
| J1815 | Injection, insulin, per 5 units | <1% | 697 | $6K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 113 | $5K |
| 87210 | <1% | 1,525 | $5K | |
| 87081 | <1% | 982 | $5K | |
| 0305 | <1% | 2,137 | $4K | |
| 73070 | <1% | 288 | $4K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 117 | $4K |
| 82550 | <1% | 760 | $4K | |
| 0258 | <1% | 1,753 | $4K | |
| 82947 | <1% | 1,006 | $4K | |
| 73560 | <1% | 255 | $4K | |
| 84439 | <1% | 626 | $4K | |
| 0410 | <1% | 211 | $4K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 224 | $4K |
| 76820 | <1% | 249 | $4K | |
| 0460 | <1% | 187 | $4K | |
| 73552 | <1% | 226 | $4K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 544 | $4K |
| 96376 | <1% | 269 | $3K | |
| A4649 | Surgical supply; miscellaneous | <1% | 3,145 | $3K |
| Q0181 | Unspecified oral dosage form, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for a iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 473 | $3K |
| 87077 | <1% | 548 | $3K | |
| 73140 | <1% | 272 | $3K | |
| 0170 | <1% | 45 | $3K | |
| 73060 | <1% | 198 | $3K | |
| 99153 | Mod sedat endo service >5yrs | <1% | 258 | $3K |
| 85018 | <1% | 1,495 | $3K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 287 | $3K |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 179 | $3K |
| 12001 | <1% | 190 | $3K | |
| 0370 | <1% | 694 | $3K | |
| 82140 | <1% | 265 | $3K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 201 | $3K |
| 86703 | <1% | 252 | $3K | |
| 0271 | <1% | 5,840 | $3K | |
| 85007 | <1% | 736 | $2K | |
| 99070 | <1% | 970 | $2K | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 411 | $2K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 287 | $2K |
| 77334 | <1% | 12 | $2K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 28 | $2K |
| 86592 | <1% | 462 | $2K | |
| 70498 | <1% | 12 | $2K | |
| 80076 | <1% | 227 | $2K | |
| 12011 | <1% | 56 | $2K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 352 | $2K |
| A4615 | Cannula, nasal | <1% | 447 | $1K |
| 82247 | <1% | 278 | $1K | |
| 85384 | <1% | 173 | $1K | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 30 | $1K |
| 84100 | <1% | 320 | $1K | |
| 29125 | <1% | 248 | $1K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 55 | $1K |
| 81002 | <1% | 464 | $1K | |
| 84550 | <1% | 276 | $1K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 26 | $1K |
| 85396 | <1% | 66 | $1K | |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 100 | $974.15 |
| 77280 | <1% | 14 | $967.94 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 126 | $798.47 |
| 72170 | <1% | 57 | $753.37 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 214 | $697.30 |
| 0306 | <1% | 1,871 | $691.60 | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 29 | $630.64 |
| 0391 | <1% | 26 | $612.18 | |
| 82248 | <1% | 137 | $572.46 | |
| 84112 | <1% | 80 | $519.61 | |
| 0324 | <1% | 614 | $513.23 | |
| 86140 | <1% | 150 | $507.91 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 40 | $496.86 |
| 73600 | <1% | 27 | $489.89 | |
| 87070 | <1% | 55 | $468.57 | |
| 86923 | <1% | 17 | $458.74 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 65 | $378.64 |
| 82565 | <1% | 84 | $344.46 | |
| 20610 | <1% | 16 | $268.36 | |
| 76857 | <1% | 12 | $262.30 | |
| 71101 | <1% | 12 | $245.23 | |
| 36416 | <1% | 296 | $213.60 | |
| 29515 | <1% | 28 | $196.79 | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 49 | $190.56 |
| 87205 | <1% | 66 | $164.57 | |
| 29130 | <1% | 13 | $148.40 | |
| 0302 | <1% | 1,522 | $132.89 | |
| 12002 | <1% | 12 | $122.52 | |
| 84520 | <1% | 26 | $102.64 | |
| 0420 | <1% | 159 | $83.54 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 15 | $79.49 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 17 | $77.15 |
| 94799 | <1% | 19 | $69.18 | |
| 82010 | <1% | 13 | $56.67 | |
| 0470 | <1% | 573 | $55.94 | |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | <1% | 12 | $54.01 |
| 0307 | <1% | 1,235 | $50.96 | |
| 0260 | <1% | 144 | $42.37 | |
| A4657 | Syringe, with or without needle, each | <1% | 101 | $10.98 |
| 0730 | 0% | 603 | $0.00 | |
| 0312 | 0% | 328 | $0.00 | |
| 0402 | 0% | 747 | $0.00 | |
| 0278 | 0% | 12 | $0.00 | |
| 0351 | 0% | 65 | $0.00 | |
| 0361 | 0% | 92 | $0.00 | |
| 0489 | 0% | 56 | $0.00 | |
| 0320 | 0% | 125 | $0.00 | |
| 0481 | 0% | 54 | $0.00 | |
| 91300 | 0% | 29 | $0.00 | |
| 0720 | 0% | 319 | $0.00 | |
| 0371 | 0% | 38 | $0.00 | |
| S9445 | Patient education, not otherwise classified, non-physician provider, individual, per session | 0% | 138 | $0.00 |
| 0352 | 0% | 277 | $0.00 | |
| 76377 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
Who's on the registration
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.